Syndax Pharmaceuticals, Inc. (SNDX)
NASDAQ: SNDX · Real-Time Price · USD
20.53
+0.63 (3.17%)
At close: Feb 24, 2026, 4:00 PM EST
20.36
-0.17 (-0.81%)
After-hours: Feb 24, 2026, 7:34 PM EST
Syndax Pharmaceuticals Employees
Syndax Pharmaceuticals had 270 employees as of December 31, 2024. The number of employees increased by 86 or 46.74% compared to the previous year.
Employees
270
Change (1Y)
86
Growth (1Y)
46.74%
Revenue / Employee
$412,237
Profits / Employee
-$1,153,989
Market Cap
1.78B
Employees Chart
Employees History
| Date | Employees | Change (1Y) | Growth (1Y) | Full-Time | Part-Time |
|---|---|---|---|---|---|
| Dec 31, 2024 | 270 | 86 | 46.74% | 270 | 0 |
| Dec 31, 2023 | 184 | 77 | 71.96% | 184 | 0 |
| Dec 31, 2022 | 107 | 48 | 81.36% | 107 | 0 |
| Dec 31, 2021 | 59 | 16 | 37.21% | 59 | 0 |
| Dec 31, 2020 | 43 | 8 | 22.86% | 43 | 0 |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| Agios Pharmaceuticals | 540 |
| Immunocore Holdings | 493 |
| MannKind | 407 |
| Ocular Therapeutix | 325 |
| Harmony Biosciences Holdings | 268 |
| Zymeworks | 263 |
| Innoviva | 127 |
| Definium Therapeutics | 74 |
SNDX News
- 1 day ago - Syndax Announces Participation in March Investor Conferences - GlobeNewsWire
- 5 days ago - Syndax to Announce Fourth Quarter and Full Year 2025 Financial Results and Host Conference Call and Webcast on February 26, 2026 - GlobeNewsWire
- 12 days ago - Syndax Pharmaceuticals' Early Launch Success Signals Continued Growth Into 2026 - Seeking Alpha
- 19 days ago - Syndax Announces Participation at the 2026 Guggenheim Emerging Outlook: Biotech Summit - GlobeNewsWire
- 20 days ago - Syndax Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) - GlobeNewsWire
- 6 weeks ago - Syndax Pharmaceuticals, Inc. (SNDX) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript - Seeking Alpha
- 6 weeks ago - Syndax Reports Preliminary 2025 Financial Highlights and Provides Business Updates at the 44th Annual J.P. Morgan Healthcare Conference - GlobeNewsWire
- 6 weeks ago - Syndax and World Orphan Drug Alliance to Launch a Multi-Regional Managed Access Program, Expanding Access to Revuforj® (revumenib) Outside the U.S. - GlobeNewsWire